- Home
- OMER
OMER
Omeros Corporation
as 11-15-2024 4:00pm EST
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
| Founded: | 1994 | Country: | United States |
| Employees: | 198 | City: | SEATTLE |
| Market Cap: | 391.1M | IPO Year: | 2009 |
| Target Price: | $9.00 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.49 - $7.51 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Omeros Corporation News
OMER Breaking Stock News: Dive into OMER Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
3 days ago
Q3 2024 Omeros Corp Earnings Call
GuruFocus.com
4 days ago
Omeros Corp (OMER) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Adjustments
Associated Press Finance
4 days ago
Omeros: Q3 Earnings Snapshot
Business Wire
4 days ago
Omeros Corporation Reports Third Quarter 2024 Financial Results
Business Wire
6 days ago
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024
MT Newswires
24 days ago
Omeros Gets FDA Rare Pediatric Disease Designation for Kidney Disease Drug Candidate
Simply Wall St.
2 months ago
Retail investors account for 52% of Omeros Corporation's (NASDAQ:OMER) ownership, while institutions account for 43%
Associated Press Finance
3 months ago
Omeros: Q2 Earnings Snapshot
Compare OMER vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OMER Omeros Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.